Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology
Mehmet Baysal,Elif Aksoy,Kübra Hilal Bedir,Deniz Özmen,Püsem Patır,Ufuk Demirci,Samet Yaman,Zehra Narlı Özdemir,Vildan Gürsoy,Esra Yıldızhan,Serkan Güven,Rafiye Çiftçiler,Yıldız İpek,İbrahim Ethem Pınar,Emine Eylem Genç,Sinan Mersin,Mehmet Can Uğur,Zeynep Tuğba Karabulut,Fehmi Hindilerden,İpek Yönal Hindilerden,Emine Gulturk,Melda Cömert,Volkan Karakuş,Nergiz Erkut,Abdülkerim Yıldız,Elif G. Ümit,Ahmet Muzaffer Demir,Reyhan Diz Küçükkaya,Ahmet Emre Eşkazan
DOI: https://doi.org/10.1007/s11239-024-03043-5
2024-11-13
Journal of Thrombosis and Thrombolysis
Abstract:BCR::ABL1 -negative myeloproliferative neoplasms (MPNs) pose a substantial risk of thrombosis, leading to significant morbidity and mortality. Anticoagulant therapy, historically based on vitamin K antagonists (VKAs), has limitations in preventing recurrent thrombotic events and managing bleeding complications. Direct oral anticoagulants (DOACs) offer a potential alternative with improved pharmacokinetics and compliance. However, evidence on DOAC efficacy and safety in MPNs remains limited, necessitating further investigation. In this multicenter retrospective study in Türkiye, we assessed real-world usage patterns and outcomes of DOACs in MPN patients. Data from 220 patients with PV, ET, or PMF receiving DOACs or VKAs for thrombosis or nonvalvular atrial fibrillation (NVAF) were collected from medical records. Thrombotic events and bleeding episodes were documented based on ISTH criteria. DOACs were used in 126 patients as first-line anticoagulant therapy or following VKAs. Ninety-four patients were on VKAs, of which 83 as a first-line treatment. There were eight thromboses (6.3%) seen in 126 DOAC patients, and similarly, seven episodes (9.4%) of thrombosis were observed in 94 patients using VKA. Major bleeding occurred in seven patients (5.6%) on DOAC and 3 (3.2%) in VKA. Thrombotic and bleeding risks were comparable between DOACs and VKAs ( p = 0.708 and p = 0.158, respectively). The incidence rate of thrombosis in the VKA group is 1.1% and in the DOAC group is 1.9%. The incidence of major bleeding in the VKA group is 0.6% and 1.6% in the DOAC group. To the best of our knowledge, our study included the largest number of MPN patients to date, comparing DOACs with VKA in terms of both efficacy and safety, which suggests DOACs as promising alternatives to VKAs for managing thrombotic risk in MPNs with manageable toxicity. Despite the limitations of retrospective studies, DOACs' benefits in terms of efficacy and compliance warrant further investigation through prospective trials. Individualized treatment decisions should consider patient-specific factors, emphasizing collaborative efforts between specialists to optimize DOAC therapy in patients with MPNs. Comparable efficacy and safety between DOACs and VKAs were observed in MPN patients.
cardiac & cardiovascular systems,peripheral vascular disease,hematology